Abstract
This study was conducted to investigate the modulatory effects of recombinant human tumor necrosis factor (rH‐TNF) and recombinant human interferon (rH‐IFN)‐α, ‐β and ‐γ, either alone or in combination, on the cytotoxicity of cisplatin, using MTT assay, against MKN‐45 (human stomach adenocarcinoma). MKN‐45 was resistant to rH‐TNF even at doses up to 103 U/ml. rH‐IFN‐γ inhibited the survival of MKN‐45 dose‐dependently, while rH‐IFN‐α and ‐β did not inhibit the survival of MKN‐45 even at the highest concentrations tested (104 U/ml). Combination of rH‐TNF with rH‐IFN‐α, ‐β or ‐γ did not significantly inhibit the survival of MKN‐45, except for a combination of 10 U/ral of rH‐TNF and 103 U/ml of rH‐IFN‐γ (P<0.05). Cisplatin inhibited the survival of MKN‐45 dose‐dependently. By the simultaneous combination of cisplatin with rH‐TNF and/or rH‐IFN‐α, ‐β or γ, cytotoxicity of cisplatin was enhanced and the combination effects were additive. The effects of rH‐TNF and rH‐IFN‐α, β and ‐γ on the modification of cytotoxicity of cisplatin were evaluated in terms of modification index (MI), demonstrating that rH‐TNF, rH‐IFN‐α, ‐β and ‐γ all augmented the cytotoxicity of cisplatin: MI values at 103 U/ml of rH‐IFN‐α, ‐β and ‐γ were 1.4, 1.4 and 2.3, respectively; those at the same concentrations of rH‐IFN‐α, ‐β and ‐γ in the presence of 10 U/ml of rH‐TNF were 3.6, 2.5 and 5.1, respectively. These results demonstrating that the cytotoxicity of cisplatin was enhanced by rH‐TNF and/or rH‐IFN‐α, ‐β or ‐γ suggest that cancer may be more effectively treated with the combination of cisplatin with these biological response modifiers than with cisplatin alone.
Keywords: Cytotoxicity, Cisplatin, rH‐TNF, rH‐IFNs, Human stomach adenocarcinoma cell line
Full Text
The Full Text of this article is available as a PDF (331.6 KB).
REFERENCES
- 1. ) Loehrer , P. J. and Einhorn , L. H.Diagnosis and treatment. Drugs five years later: cisplatin . Ann, Intern. Med. , 100 , 704 – 713 ( 1984. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Le Chevalier , T. , Smith , F. P. , Harter , W. K. and Schein , P. S.Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma . Semin. Oncol. , 12 , 46 – 53 ( 1985. ). [PubMed] [Google Scholar]
- 3. ) Mihich , E.Future perspectives for biological response modifiers: a viewpoint . Semin. Oncol , 13 , 234 – 254 ( 1986. ). [PubMed] [Google Scholar]
- 4. ) Inoue , M. and Tan , Y. H.Enhancement of actinomycin D‐ and cis‐diamimnedichloroplatinum(II)‐induced killing of human fibroblasts by human β‐interferon . Cancer Res. , 43 , 5484 – 5488 ( 1983. ). [PubMed] [Google Scholar]
- 5. ) Welander , C. E. , Morgan , T. M. , Homesley , H. D. , Trotta , P. P. and Spiegel , R. J.Combined recombinant human interferon alpha2 and cytotoxic agents studied in a clonogenic assay . Int. J. Cancer , 35 , 721 – 729 ( 1985. ). [DOI] [PubMed] [Google Scholar]
- 6. ) Borden , E. C. and Hawkins , M. J.Biologic response modifiers as adjuncts to other therapeutic modalities . Semin. Oncol. , 13 , 144 – 152 ( 1986. ). [PubMed] [Google Scholar]
- 7. ) Bonnem , E. M.Alfa interferon: combinations with other antineoplastic modalities . Semin. Oncol. , 14 , 48 – 60 ( 1987. ). [PubMed] [Google Scholar]
- 8. ) Kondo , H. , Tanaka , N. and Orita , K.Antitumor effect of human recombinant interferon‐γ alone or in combination with adriamycin on a human colon cancer cell line (RPMI 4788) in vitro and in nude mice . Jpn. J. Cancer Res. , 78 , 1400 – 1408 ( 1987. ). [PubMed] [Google Scholar]
- 9. ) Ostrove , J. M. and Gifford , Q. E.Stimulation of RNA synthesis in L929 cells by rabbit tumor necrosis factor . Proc. Soc. Exp. Bid. Med. , 160 , 354 – 358 ( 1979. ). [DOI] [PubMed] [Google Scholar]
- 10. ) Gatanaga , T. , Takahashi , K. , Yamazaki , M. , Mizuno , D. and Abe , S.Combination antitumor therapy with rabbit tumor necrosis factor and chemo‐ and immuno‐therapeutic agents against murine tumors . Jpn. J. Cancer. Res. , 76 , 631 – 636 ( 1985. ). [PubMed] [Google Scholar]
- 11. ) Creasey , A. A. , Reynolds , M. T. and Laird , W.Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor . Cancer Res. , 46 , 5687 – 5690 ( 1986. ). [PubMed] [Google Scholar]
- 12. ) Fransen , L. , Van der Heyden , J. , Ruysschaert , R. and Fiers , W.Recombinant tumor necrosis factor: its effect and its synergism with interferon‐γ on a variety of normal and transformed human cell lines . Eur. J. Cancer Clin. Oncol. , 22 , 419 – 426 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 13. ) Balkwill , F. R. , Lee , A. , Aldam , G. , Moodie , E. , Thomas , J. A. , Tavenier , J. and Fiers , W.Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons . Cancer Res. , 46 , 3990 – 3993 ( 1986. ). [PubMed] [Google Scholar]
- 14. ) Hong , W‐S. , Jett , J. R. , Sasaki , Y. , Takahashi , H. , Nakano , H. , Nakagawa , K. , Hoshi , A. and Saijo , N.Colony inhibitory effect of recombinant human tumor necrosis factor (rH‐TNF) and/or recombinant human interferon (rH‐IFN)‐α, ‐β and ‐γ on human lung cancer cell lines . Jpn. J. Clin. Oncol. , 17 , 49 – 55 ( 1987. ). [PubMed] [Google Scholar]
- 15. ) Naomoto , Y. , Tanaka , N. , Fuchimoto , S. and Orita , K.In vitro synergistic effects of natural human tumor necrosis factor and natural human interferon‐α . Jpn. J. Cancer Res. , 78 , 87 – 92 ( 1987. ). [PubMed] [Google Scholar]
- 16. ) Mosmann , T.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays . J. Immunol. Methods , 65 , 55 – 63 ( 1983. ). [DOI] [PubMed] [Google Scholar]
- 17. ) Hong , W‐S. , Saijo , N. , Sasaki , Y. , Minato , K. , Nakano , H. , Nakagawa , K. , Fujiwara , Y. , Nomura , K , and Twentyman , P. R.Establishment and characterization of cisplatin‐resistant sublines of human lung cancer cell lines . Int. J. Cancer , 41 , 462 – 467 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 18. ) Momparler , R. L.In vitro systems for evaluation of combination chemotherapy . Pharmacol. Ther. , 8 , 21 – 35 ( 1980. ). [Google Scholar]
- 19. ) Hong , W‐S. , Saijo , N. , Sasaki , Y. , Shinkai , T. , Eguchi , K. , Sakurai , M. , Takahashi , H. , Nakano , H. , Nakagawa , K. and Twentyman , P. R.In vitro growth inhibition of cisplatin‐resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon‐γ by virtue of collateral sensitivity . Jpn. J. Cancer Res. , 78 , 1274 – 1280 ( 1987. ). [PubMed] [Google Scholar]
- 20. ) Carswell , E. A. , Old , L. J. , Kassel , R. L. , Green , S. , Fiore , N. and Williamson , B.An endotoxin‐induced serum factor that causes necrosis of tumors . Proc. Natl. Acad. Sci. USA , 72 , 3666 – 3670 ( 1975. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. ) Kull , F. C. , Jacobs , S. and Cuatrecasas , P.Cellular receptor for 125I‐labeled tumor necrosis factor: specific binding affinity labeling and relationship to sensitivity . Proc. Natl. Acad. Sci. USA , 82 , 5756 – 5760 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. ) Ruff , M. R. and Gilford , G. E.Purification and physicochemical characterization of rabbit tumor necrosis factor . J. Immunol. , 125 , 1671 – 1677 ( 1980. ). [PubMed] [Google Scholar]
- 23. ) Sasaki , Y. , Kanzawa , F. , Takahashi , H. , Matsushima , Y. , Nakano , H. , Nakagawa , K. , Hong , W‐S. , Minato , K. , Fujiwara , Y. and Saijo , N.In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay. Invest . New Drugs , 5 , 353 – 359 ( 1987. ). [DOI] [PubMed] [Google Scholar]